# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mahalia Jackson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML035-SYN
- Date: 2026-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Beatrice Fontenot, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review after nine weeks of treatment. **S**

## History of present illness

Ms. Jackson returns nine weeks after starting prednisone and methotrexate. The electrophysiology study induced sustained ventricular tachycardia, and a dual-chamber defibrillator was placed the next day; the wound has healed and she has had no shocks. The remote transmission last week showed two short runs of ventricular tachycardia in March and none since. She climbs two flights before stopping, the cough has gone, and the palpitations are rare. She has had a large appetite, gained weight, and sleeps poorly on prednisone. Home glucose readings are 100 to 130 mg/dL. She has had no mouth sores, nausea or infections on methotrexate, and drinks no alcohol. The final EBUS cultures were negative. No methotrexate blood tests have been done since she started. She is eager to sing again and has concerts offered from the end of May. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Device | Dual-chamber defibrillator since the electrophysiology study; no shocks; two runs of ventricular tachycardia in March, none since |
| Symptoms | Two flights of stairs; cough gone; palpitations rare |
| Steroid effects | Large appetite, weight up 2.8 kg, poor sleep; home glucose 100 to 130 mg/dL |
| Methotrexate | 15 mg weekly; no mouth sores or nausea; no blood tests since starting |
| Work | Concerts offered from the end of May |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Large appetite; weight 94.0 kg; no fever |
| Respiratory | Negative | Cough gone; breathless only on the second flight |
| Cardiovascular | Negative | Palpitations rare; no shocks, fainting or ankle swelling |
| Ears, nose, mouth, and throat | Negative | No mouth sores or thrush; voice strong |
| Endocrine | Positive | Home glucose 100 to 130 mg/dL; no thirst |
| Psychiatric | Positive | Poor sleep on prednisone; mood good; PHQ-9 5; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks **S**
- Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays **S**
- Folic acid 1 mg oral tablet, one tablet by mouth daily **S**
- Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food **S**
- Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutes **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 138/86 mmHg; pulse 66 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 94 kg; BMI 32.5 kg/m². All vital signs are synthetic.

Hemoglobin: 13.1 g/dL; White cell count: 9.8 10*3/uL; Lymphocyte count: 1.2 10*3/uL; Platelets: 262 10*3/uL; Sodium: 139 mmol/L; Potassium: 3.9 mmol/L; Creatinine: 0.92 mg/dL; eGFR (CKD-EPI 2021): 75 mL/min/1.73 m²; Glucose: 118 mg/dL (high); Calcium: 9.6 mg/dL; ALT: 31 U/L; AST: 28 U/L; Alkaline phosphatase: 96 U/L; Albumin: 4.1 g/dL; Hemoglobin A1c: 6.3% (high); 25-hydroxyvitamin D: 24 ng/mL (low); NT-proBNP: 140 pg/mL (high); FVC percent predicted: 84%; FEV1 percent predicted: 85%; FEV1/FVC ratio: 80%; DLCO percent predicted: 70% (low); PHQ-9: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 13.1 g/dL at this visit **S**
- White cell count: 4.6 10*3/uL at baseline, 9.8 10*3/uL at this visit **S**
- Lymphocyte count: 0.9 10*3/uL (low) at baseline, 1.2 10*3/uL at this visit **S**
- Platelets: 232 10*3/uL at baseline, 262 10*3/uL at this visit **S**
- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 3.9 mmol/L at this visit **S**
- Creatinine: 1.08 mg/dL (high) at baseline, 0.92 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 62 mL/min/1.73 m² at baseline, 75 mL/min/1.73 m² at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 118 mg/dL (high) at this visit **S**
- Calcium: 10.8 mg/dL (high) at baseline, 9.6 mg/dL at this visit **S**
- ALT: 28 U/L at baseline, 31 U/L at this visit **S**
- AST: 30 U/L at baseline, 28 U/L at this visit **S**
- Alkaline phosphatase: 128 U/L (high) at baseline, 96 U/L at this visit **S**
- Albumin: 4 g/dL at baseline, 4.1 g/dL at this visit **S**
- Hemoglobin A1c: 5.9% (high) at baseline, 6.3% (high) at this visit **S**
- 25-hydroxyvitamin D: 22 ng/mL (low) at baseline, 24 ng/mL (low) at this visit **S**
- NT-proBNP: 210 pg/mL (high) at baseline, 140 pg/mL (high) at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 94.0 kg; blood pressure 138/86, pulse 66 and regular |
| Respiratory | Clear to auscultation |
| Cardiovascular | Regular rhythm; no murmur; defibrillator pocket healed without swelling or tenderness |
| Mouth | No thrush or ulcers |
| Skin | Mild facial fullness; no bruising or infection |
| Psychiatric | Cheerful, impatient to sing |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cardiac sarcoidosis on treatment, with a defibrillator** (D86.85). Clinically better: rare palpitations, no ventricular tachycardia since March, NT-proBNP 140 pg/mL from 240. The defibrillator protects her against sudden death while the inflammation settles. **S**
   - Prednisone taper: 30 mg daily for four weeks, then 20 mg for four weeks, 15 mg for four weeks, and 10 mg until the review in August.
   - Methotrexate increased to 20 mg once weekly.
   - Continue metoprolol; monthly remote device checks; clinic device check in three months.
   - Repeat FDG-PET and echocardiogram in mid-August.
2. **Implantable cardioverter-defibrillator** (Z95.810). Wound healed; she may drive again and lift her left arm fully. Singing and stage movement are safe; she should keep mobile phones and headphones 15 cm from the device and walk through airport security with her device card. **S**
   - Device card and travel letter given.
   - Remote monitor travels with her.
3. **Pulmonary sarcoidosis** (D86.2). Lung function improving: FVC 84 percent from 74, DLCO 70 percent from 62. **S**
   - Repeat lung function in August.
4. **Hypercalcemia** (E83.52). Calcium 9.6 mg/dL, normal on prednisone; resolved. Vitamin D can now be replaced cautiously: 25-hydroxyvitamin D 24 ng/mL. **S**
   - Cholecalciferol 1000 units daily, with calcium at the next visit.
   - Problem resolved.
5. **Long-term systemic glucocorticoid treatment** (Z79.52). Steroid effects: blood pressure 138/86, glucose 118 mg/dL and A1c 6.3% (from 5.9%), weight up 2.8 kg, poor sleep. Bone density in March showed moderate fracture risk; on alendronate since. **S**
   - Prednisone in the morning only; reduce salt and sweet drinks; walk daily.
   - Blood pressure at home twice a week; treat if it stays above 130/80 after the taper.
   - Stop atovaquone when prednisone falls below 20 mg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Spirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO) | At diagnosis, three months after starting treatment, then every three to six months while treatment changes | Completed today | FVC 84 percent, FEV1 85 percent, FEV1/FVC 80 percent, DLCO 70 percent of predicted |
| Laboratory | Methotrexate safety: blood count, liver tests and creatinine | Before starting; every two to four weeks for the first three months; then every eight to twelve weeks | Deferred | A deviation: the blood count, liver tests and creatinine due two to four weeks after methotrexate began were not done, because no laboratory order was placed for the long gap between visits. No harm resulted: today hemoglobin 13.1 g/dL, white cells 9.8 (raised by prednisone), lymphocytes 1.2, platelets 262, ALT 31, AST 28, alkaline phosphatase 96 U/L, albumin 4.1 g/dL, creatinine 0.92 mg/dL and eGFR 75 are normal. Corrective action: standing orders every four weeks until twelve weeks and then every eight to twelve weeks, at a laboratory near home or on tour, with a reminder to her and to the clinic |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 9.6 mg/dL, normal |
| Laboratory | Electrolytes | At each visit on glucocorticoids | Completed today | Sodium 139, potassium 3.9 mmol/L |
| Laboratory | 25-hydroxyvitamin D | Before replacement and after it starts | Completed today | 24 ng/mL; replacement started now that calcium is normal |
| Laboratory | Glucose and A1c on glucocorticoids | At each visit; A1c every three months | Completed today | Glucose 118 mg/dL; A1c 6.3% |
| Laboratory | NT-proBNP | At each cardiac review | Completed today | 140 pg/mL |
| Examination | Blood pressure and weight on glucocorticoids | Each visit | Completed today | 138/86 mmHg; weight 94.0 kg, up 2.8 kg |
| Imaging | Bone density (DXA) and FRAX | At the start of long-term glucocorticoids, then every one to three years | Up to date | March: femoral neck T-score -1.6; moderate risk; alendronate |
| Examination | Defibrillator check (remote and in clinic) | Remote transmissions monthly and with any symptom; clinic check every three to six months | Completed today | Remote transmission last week: two runs of nonsustained ventricular tachycardia in March, none since; no therapies; normal lead values |
| Laboratory | Exclusion of other granulomatous causes | At diagnosis | Up to date | Final mycobacterial and fungal cultures negative at eight weeks |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Completed today | Atovaquone continues until prednisone falls below 20 mg |
| Medication safety | Vaccination on immunosuppression | Per schedule | Completed today | Hepatitis B dose 2 given today, completing the two-dose series; zoster dose 2 due in August |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 5 |
| Self-management | Performing and travel plan | At each visit | Completed today | Two concerts a week in the United States from the end of May, with a rest day after each; no international touring until after the August PET; voice care; travel letter and device card |

## Goal progress

- Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation. Outcome by 2026-03-09: EBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeks. **S**
- Calcium in the normal range within three months. Outcome by 2026-05-11: Calcium 9.6 mg/dL after nine weeks of treatment. **S**
- FVC and DLCO improved by at least 10 percent of predicted within six months. In progress; target 2026-08-24. **S**
- No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better. In progress; target 2026-08-24. **S**
- Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent. In progress; target 2026-08-24. **S**
- Back on stage with a schedule she can sustain, with her voice protected. In progress; target 2026-08-24. **S**

## Medication changes

- Stopped: Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning **S**
- Started: Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks **S**
- Stopped: Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays **S**
- Started: Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays **S**
- Started: Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily **S**

## Guideline basis

- Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021), European Respiratory Society
- Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014), Heart Rhythm Society
- Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024), American Heart Association
- Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022), American College of Rheumatology
- Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012), American College of Rheumatology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Methotrexate blood tests every four weeks. Remote device checks monthly. Review in mid-August after the repeat FDG-PET, echocardiogram and lung function. Call for fever, cough, breathlessness, a shock, or fainting. **S**
- Next scheduled visit 2026-08-24: six months of treatment: repeat FDG-PET, steroid taper, and plans for touring. **S**
